Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00477750 · OUTCOME

Duration of Response (DOR)

Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma · Source last updated 2019-10-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
from first response to progression or death (up to 3 years)

What was measured

Duration of response was calculated from documentation of first response to date of progression in the subset of patients who responded. Patients without progression were censored at the date of last tumor evaluation.

Analysis population: Phase 2 Patients who had a response of PR or better are included in this analysis.

Groups in this outcome

Treatment (Lenalidomide, Melphalan, Prednisone)

Intervention: Drug: lenalidomide 10 mg orally days 1-21 every 28 days until progression Intervention: Drug: melphalan 5mg/m\^2 orally days 1-4 every 28 days until progression Intervention: Drug: prednisone 60mg/m\^2, orally days 1-4 every 28 days until progression

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Lenalidomide, Melphalan, Prednisone)18

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Lenalidomide, Melphalan, Prednisone)16.3Not reported14.326.4Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        14.3
        upper Limit
        26.4
        value
        16.3
denoms
  1. counts
    1. group Id
      OG000
      value
      18
    units
    Participants
description
Duration of response was calculated from documentation of first response to date of progression in the subset of patients who responded. Patients without progression were censored at the date of last tumor evaluation.
dispersion Type
95% Confidence Interval
groups
  1. description
    Intervention: Drug: lenalidomide 10 mg orally days 1-21 every 28 days until progression Intervention: Drug: melphalan 5mg/m\^2 orally days 1-4 every 28 days until progression Intervention: Drug: prednisone 60mg/m\^2, orally days 1-4 every 28 days until progression
    id
    OG000
    title
    Treatment (Lenalidomide, Melphalan, Prednisone)
param Type
MEDIAN
population Description
Phase 2 Patients who had a response of PR or better are included in this analysis.
reporting Status
POSTED
time Frame
from first response to progression or death (up to 3 years)
title
Duration of Response (DOR)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice